Is ECT cost-effective? A critique of the National Institute of Health and Clinical Excellence's report on the economic analysis of ECT

Journal of ECT

Volumn 22, Issue 1, 2006, Pages 25-29

  McDonald, William M ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cost effective; ECT; NICE report

Indexed keywords

ANTIDEPRESSANT AGENT; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; LITHIUM CHLORIDE; NEUROLEPTIC AGENT; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ABSENTEEISM; COMORBIDITY; CONFIDENCE INTERVAL; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DEPRESSIVE PSYCHOSIS; DRUG COST; DRUG EFFECT; DRUG EFFICACY; ELECTROCONVULSIVE THERAPY; EVALUATION; HAMILTON SCALE; HEALTH CARE ORGANIZATION; HEALTH CARE UTILIZATION; HEALTH MAINTENANCE ORGANIZATION; HOSPITALIZATION; HUMAN; MAJOR DEPRESSION; MANAGED CARE ORGANIZATION; MONTGOMERY ASBERG DEPRESSION RATING SCALE; OUTPATIENT CARE; PROBABILITY; QUALITY OF LIFE; REVIEW; COST; ECONOMICS; QUALITY ADJUSTED LIFE YEAR; RECURRENT DISEASE;

ANTIDEPRESSIVE AGENTS; COSTS AND COST ANALYSIS; DEPRESSIVE DISORDER, MAJOR; ELECTROCONVULSIVE THERAPY; HUMANS; QUALITY-ADJUSTED LIFE YEARS; RECURRENCE;

EID: 33748465720     PISSN: 10950680     EISSN: 15334112     Source Type: Journal    
DOI: 10.1097/00124509-200603000-00005     Document Type: Review

References (32)

1. National Institute of Clinical Excellence. Technology Appraisal Guidance 59: Guidance on the Use of Electroconvulsive Therapy. London, England: National Institute for Clinical Excellence, 2003.
2. Greenhalgh J, Knight C, Hind D, et al. Clinical and cost-effectiveness of electroconvulsive therapy for depressive illness, schizophrenia, catatonia and mania: systematic reviews and economic modelling studies. Health Technol Assess. 2005;9(9):1-156.
3. Riotto M. Depression in the workplace: negative effects, perspective on drug costs and benefit solutions. Benefits Q. 2001;17(2):37-48.
4. Prudic J, Haskett RF, Mulsant B, et al. Resistance to antidepressant medications and short-term clinical response to ECT [see comment]. Am J Psychiatry. 1996;153(8):985-992.
5. Petrides G, Fink M, Husain MM, et al. ECT remission rates in psychotic versus nonpsychotic depressed patients: a report from CORE. J ECT. 2001;17(4):244-253.
6. O'Connor MK, Knapp R, Husain M, et al. The influence of age on the response of major depression to electroconvulsive therapy: a C.O.R.E. report. Am J Geriatr Psychiatry. 2001;9(4):382-390.
7. Khan A, Kolts RL, Thase ME, et al. Research design features and patient characteristics associated with the outcome of antidepressant clinical trials. Am J Psychiatry. 2004;161(11):2045-2049.
8. Thase ME. Treatment alternatives for difficult to treat depression: What is the state of the evidence? Psychiatric Annals. 2003;33:813-827.
9. Doyle JJ, Casciano J, Arikian S, et al. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs. Value Health. 2001;4:16-31.
10. Freeman H, Arikian S, Lenox-Smith A. Pharmacoeconomic analysis of antidepressants for major depressive disorder in the United Kingdom. Pharmacoeconomics. 2000;18:143-148.
11. Einarson TR, Arikian S, Sweeney S, et al. A model to evaluate the cost-effectiveness of oral therapies in the management of patients with major depressive disorders. Clin Ther. 1995;17(1):136-153.
12. Prudic J, Sackeim HA, Devanand DP. Medication resistance and clinical response to electroconvulsive therapy. Psychiatry Res. 1990;31(3):287-296.
13. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors [see comment]. Br J Psychiatry. 2001;178:234-241.
14. Husain MM, Rush AJ, Fink M, et al. Speed of response and remission in major depressive disorder with acute electroconvulsive therapy (ECT): a Consortium for Research in ECT (CORE) report. J Clin Psychiatry. 2004;65:485-491.
15. Folkerts HW, Michael N, Tolle R. Electroconvulsive therapy vs. paroxetine in treatment-resistant depression - a randomized study. Acta Psychiatr Scand. 1997;96(5):334-342.
16. Hirschfeld RM. Clinical importance of long-term antidepressant treatment. Br J Psychiatry Suppl. 2001;42(8):0.
17. Sackeim HA, Haskett RF, Mulsant BH, et al. Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial [see comment]. JAMA. March 14, 2001;285(10):1299-1307.
18. Sackeim HA, Prudic J, Devanand DP. The impact of medication resistance and continuation pharmacotherapy on relapse following response to electroconvulsive therapy in major depression. J Clin Psychopharmacol. 1990;10(2):96-104.
19. Flint AJ, Rifat SL. The treatment of psychotic depression in later life: a comparison of pharmacotherapy and ECT. Int J Geriatr Psychiatry. 1998;13(1):23-28.
20. Olfson M, Marcus S, Sackeim HA, et al. Use of ECT for the inpatient treatment of recurrent major depression. Am J Psychiatry. 1998;155(1):22-29.
21. Corey-Lisle PK, Birnbaum HG, Greenberg PE, et al. Identification of a claims data "signature" and economic consequences for treatment-resistant depression. J Clin Psychiatry. 2002;63(8):717-726.
22. Greenberg PE, Finkelstein SN, Berndt ER. Calculating the workplace cost of chronic disease. Bus Health. September 1995;13(9):27-28, 30.
23. Greenberg PE, Stiglin LE, Finkelstein SN, et al. The economic burden of depression in 1990 [see comment]. J Clin Psychiatry. November 1993;54(11):405-418.
24. Jimenez RE, Lam RM, Marot M. Observed-predicted length of stay for an acute psychiatric department, as an indicator of inpatient care inefficiencies. Retrospective case-series study. BMC Health Serv Res. February 17, 2004;4(1):4.
25. Unutzer J, Patrick DL, Diehr P, et al. Quality adjusted life years in older adults with depressive symptoms and chronic medical disorders. Int Psychogeriatr. March 2000;12(1):15-33.
26. Unutzer J, Patrick DL, Simon G, et al. Depressive symptoms and the cost of health services in HMO patients aged 65 years and older. A 4-year prospective study. JAMA. May 28, 1997;277(20):1618-1623.
27. Wells K.B., Burnam MA.. Caring for depression in America: lessons learned from early findings of the medical outcomes study. Psychiatr Med. 1991;9(4):503-519.
28. Wells KB, Burnam MA, Rogers W, et al. The course of depression in adult outpatients. Results from the Medical Outcomes Study. Arch Gen Psychiatry. October 1992;49(10):788-794.
29. Wells KB, Golding JM, Burnam MA. Psychiatric disorder and limitations in physical functioning in a sample of the Los Angeles general population. Am J Psychiatry. June 1988;145(6):712-717.
30. Wells KB, Stewart A, Hays RD, et al. The functioning and well-being of depressed patients. Results from the Medical Outcomes Study [see comment]. JAMA. August 18, 1989;262(7):914-919.
31. Simon GE, VonKorff M, Barlow W. Health care costs of primary care patients with recognized depression. Arch Gen Psychiatry. 1995;52(10):850-856.
32. Shoor R. The Consequences of Depression. State of Health Care in America, 1994.